Ann-Cathrin Radesäter

TL;DR: AR-A014418 is the first compound of a family of specific inhibitors of GSK3 that does not significantly inhibit closely related kinases such as cdk2 or cdk5 and may have important applications as a tool to elucidate the role of Gsk3 in cellular signaling and possibly in Alzheimer's disease.

TL;DR: Novel in vivo active γ-secretase modulators are described that are selective for Aβ modulation and do not impair processing of Notch, EphB2, or EphA4 and provide compelling evidence of a growing class of in vivoactive GSMs, which are selectively for A β modulation and have a different mechanism of action compared with the original class of GSMs described.

TL;DR: In this article, the authors reported the discovery and the pharmacokinetic and pharmacodynamic properties of BACE1 inhibitor AZ-4217, a high potency compound with an excellent in vivo efficacy.

TL;DR: An in vitro model for investigating effects of the amyloid β (Aβ)-peptide on pyramidal neuron degeneration, glial cell activation and tau phosphorylation may constitute a useful tool for screening novel drugs against Aβ-induced alterations of tau and degeneration of hippocampal neurons.

TL;DR: The neuroprotective effects exerted by trolox and MK-801 suggest that free radicals and NMDA receptor-mediated processes are involved in IL-1β-induced neurodegeneration.